Skip to main content
. 2023 Aug 22;52(6):1716–1724. doi: 10.1093/ije/dyad114

Table 1.

Socio-demographic characteristics of the study population and stratified for individuals who received a third dose and/or a fourth dose over the study period

Study population Third-dose recipients a Fourth-dose recipients


Monovalent vaccine
BA.1 bivalent vaccine
BA.4–5 bivalent vaccine
n % n % n % n % n %
Sex
 Female 227 290 55.70 214 120 55.60 142 665 55.04 18 621 53.38 13 781 54.00
 Male 180 783 44.30 170 744 44.40 116 514 44.96 16 260 46.62 11 741 46.00
Age (years)
 75–79 194 594 47.70 191 434 49.70 122 884 47.41 19 733 56.57 13 589 53.24
 80–84 111 271 27.30 100 959 26.20 72 288 27.89 8596 24.64 6439 25.23
 85–89 63 264 15.50 57 243 14.90 39 867 15.38 4355 12.49 3524 13.81
 90+ 38 944 9.50 35 228 9.20 24 140 9.31 2197 6.30 1970 7.72
Region
 Innlandet 36 022 8.80 33 868 8.80 22 451 8.66 3808 10.92 2072 8.12
 Trøndelag 36 702 9.00 34 878 9 23 618 9.00 3038 9.00 1807 7.00
 Nord-Norge 39 775 9.70 38 615 10.00 20 636 7.96 3683 10.56 3264 12.79
 Oslo & Viken 133 582 32.70 123 735 32.20 87 962 33.94 10 611 30.42 9809 38.43
 Agder & Sørøstlandet 60 375 14.80 56 980 14.80 38 368 14.80 5074 14.55 4052 15.88
 Vestlandet 101 617 24.90 96 788 25.10 66 144 25.52 8667 24.85 4518 17.70
Risk group
 None 189 581 46.50 179 726 46.70 120 725 46.58 16 549 47.44 11 973 46.91
 Medium 187 608 46.10 176 342 45.80 118 653 45.78 15 865 45.48 11 706 45.87
 High 30 884 7.60 28 796 7.50 19 801 7.64 2467 7.07 1843 7.22
LTCF resident
 No 388 227 95.10 367 392 95.50 244 997 94.53 34 472 98.83 25 086 98.29
 Yes 19 846 4.90 17 472 4.50 14 182 5.47 409 1.17 436 1.71

LTCF, long-term care facility. n, number.

a

Individuals who received their third dose >24 weeks ago.